


**Figure 1. Interim population PK analysis of dose-normalized (8 mg/day) perampanel plasma concentrations in patients aged >6 to <24 months compared with those observed in older children (aged 2–10 years), adolescents (aged 11–17 years), and adults (aged  $\geq 18$  years) for (A) patients who were receiving non-EIASMs and (B) patients who were receiving EIASMs**



EIASM, enzyme-inducing anti-seizure medication; PK, pharmacokinetic